Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors

被引:0
|
作者
Yared, Jean A. [1 ]
Lee, Tsung-Ying [2 ]
Cooke, Catherine E. [2 ]
Johnson, Abree [2 ]
Summers, Amanda [2 ]
Yang, Keri [3 ]
Liu, Sizhu [3 ]
Tang, Boxiong [3 ]
Onukwugha, Eberechukwu [2 ]
机构
[1] Univ Maryland, Sch Med, Dept Med, Baltimore, MD USA
[2] Univ Maryland, Sch Pharm, Dept Practice Sci & Hlth Outcomes Res, 220 Arch St, Baltimore, MD 21201 USA
[3] Beigene USA Inc, San Mateo, CA USA
关键词
Treatment patterns; social determinants of health; social vulnerability index; chronic lymphocytic leukemia; INITIAL THERAPY; IBRUTINIB; CANCER; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; VENETOCLAX; RITUXIMAB;
D O I
10.1080/10428194.2024.2310150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study characterizes the patterns and timing of CLL treatment and, to our knowledge, is the first to identify social vulnerability factors associated with CLL treatment receipt in the Medicare population. A total of 3508 Medicare beneficiaries diagnosed with CLL from 2017 to 2019 were identified. We reported the proportion of individuals who received CLL treatment and the time until the first CLL treatment receipt after the first observed claim with a CLL diagnosis. Logistic regression and time-to-event models provided adjusted odds ratios and hazard ratios associated with baseline individual-level and county-level factors. Sixteen percent of individuals received CLL treatment, and the median follow-up time was 540 d. The median time to receipt of CLL treatment was 61 d. Older age and residence in a county ranked high in social vulnerability (as defined by minority status and language) were negatively associated with treatment receipt and time to treatment receipt.
引用
收藏
页码:598 / 608
页数:11
相关论文
共 50 条
  • [41] Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials
    Vidal, Liat
    Gurion, Ronit
    Ram, Ron
    Raanani, Pia
    Bairey, Osnat
    Robak, Tadeusz
    Gafter-Gvili, Anat
    Shpilberg, Ofer
    LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2047 - 2057
  • [42] Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease
    Sugiura, Hiroyuki
    Sezaki, Nobuo
    Ishikawa, Tatsunori
    Kuroi, Taiga
    Okamoto, Sachiyo
    Nomura, Naho
    Masunari, Taro
    Nakasako, Yukio
    Kiguchi, Toru
    Tanimoto, Mitsune
    CLINICAL CASE REPORTS, 2022, 10 (04):
  • [43] Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis
    Nunes, Altacilio Aparecido
    da Silva, Anderson Soares
    Souza, Kathiaja Miranda
    Silva Koury, Christine de Nazare
    de Mello, Luane Marques
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 261 - 269
  • [44] Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)
    Alrawashdh, Neda
    Sweasy, Joann
    Erstad, Brian
    McBride, Ali
    Persky, Daniel O.
    Abraham, Ivo
    ANNALS OF HEMATOLOGY, 2021, 100 (10) : 2501 - 2512
  • [45] Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel
    Weil, Clara
    Chodick, Gabriel
    Shalev, Varda
    Kan, Inna
    Afik, Ran
    Cohen, Raanan
    Sail, Kavita
    Herishanu, Yair
    LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1136 - 1145
  • [46] Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome
    Albi, Elisa
    Baldoni, Stefano
    Aureli, Patrizia
    Dorillo, Erica
    Del Papa, Beatrice
    Ascani, Stefano
    Di Ianni, Mauro
    Falzetti, Franca
    Sportoletti, Paolo
    TUMORI, 2017, 103 : S37 - S40
  • [47] RECURRENCE OF AUTOIMMUNE THROMBOCYTOPENIA AFTER TREATMENT WITH FLUDARABINE IN A PATIENT WITH CHRONIC LYMPHOCYTIC-LEUKEMIA
    MONTILLO, M
    TEDESCHI, A
    LEONI, P
    LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 187 - 188
  • [48] Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
    Iskender, Gulsen
    Iskender, Dicle
    Ertek, Mustafa
    TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (03) : 208 - 209
  • [49] The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia
    Pamuk, Gulsum Emel
    Turgut, Burhan
    Demir, Muzaffer
    Tezcan, Fatma
    Vural, Ozden
    AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (08) : 631 - 633
  • [50] Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis
    Pollard, Samantha
    Chan, Brandon
    Gerrie, Alina S.
    Raymakers, Adam J. N.
    Regier, Dean A.
    SCIENTIFIC REPORTS, 2024, 14 (01):